AB1027 creates a more prescriptive quality‑assurance regime for commercially sold cannabis and cannabis products. It specifies what must appear on certificates of analysis, defines a set of contaminants and chemical components to test for, and formalizes procedural requirements—sampling, chain of custody, retesting, and sample disposition.
The bill also raises the technical bar for testing laboratories by requiring standardized methods, performance testing programs, and accreditation criteria. Those changes aim to produce more consistent test results and clearer consumer-facing labeling, but they also shift compliance costs onto labs, producers, and the state regulator responsible for writing and enforcing the implementing standards.
At a Glance
What It Does
The bill requires representative sampling of batches and compliance testing of the product’s final consumer form, with licensed testing laboratories issuing certificates of analysis at a department‑determined frequency that include chemical profile conformity and contaminant status. It adds procedural safeguards: documented chain of custody, retest protocols, destruction of residual samples, and the ability for laboratories to correct minor certificate errors.
Who It Affects
Primary targets are licensed testing laboratories, cultivators and manufacturers that must submit batches for compliance testing, and retailers that cannot sell until testing requirements are met. The Department responsible for regulation must write methods, tolerance levels, and accreditation rules that implement the law.
Why It Matters
AB1027 pushes California toward uniform laboratory practices (including standardized cannabinoid test methods and accreditation requirements) to reduce inter‑laboratory variability and consumer risk. That standardization increases regulatory clarity but concentrates implementation risk in department rulemaking and in laboratories’ capacity to meet stricter technical requirements.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB1027 lays out a compliance testing framework that attaches to each batch of commercially sold cannabis or cannabis products. The bill mandates that samples be taken and tested in the final form that consumers will use—edible, oil, flower, etc.—and it requires testing only by laboratories licensed to perform compliance testing.
Laboratories must produce a certificate of analysis for selected lots at a frequency the department sets, and those certificates must include both whether the product’s chemical profile matches labeled compound content and whether contaminants stay below departmentestablished thresholds.
The statute enumerates a set of chemical constituents that certificates must address unless the department narrows them by regulation: THC, THCA, CBD, CBDA, specified terpenes, CBG, CBN, and other compounds the department requires. It defines contaminants broadly to include residual solvents and processing chemicals, foreign material (hair, insects), and microbiological impurities; the department must consider external references—such as the American Herbal Pharmacopoeia and Department of Pesticide Regulation guidance—when setting limits.
For edible products the bill puts a numerical cap on THC per serving (a 10‑milligram target with defined allowable variance and a post‑specified‑date tighter tolerance), and it directs the department to create adjusted variance rules for low‑dose edibles under five milligrams.On laboratory operations, AB1027 requires standardized test methods for cannabinoids (the department must establish at least one method and operating procedures) and directs laboratories to follow general competence standards for testing and sampling. The bill requires testing labs to obtain and maintain ISO/IEC 17025 accreditation as the department’s regulations specify.
To check inter‑laboratory consistency, the department may run performance testing programs—blind proficiency, round‑robin, or similar approaches—subject to legislative appropriation. The text also prescribes operational controls: standard operating procedures for confirming or refuting out‑of‑spec results, limited conditions that permit retesting, destruction of leftover samples per department rulemaking, and chain‑of‑custody requirements for transfers and presale inspections.Finally, AB1027 preserves a narrow role for licensees to perform onsite testing for quality control and business operations, including of products from other licensees, but it makes clear that onsite testing is not certified by the department and does not replace the requirement for third‑party compliance testing at a licensed testing laboratory.
The Five Things You Need to Know
Department sets frequency and selection: the bill lets the department determine which lots are tested or retested and how often laboratories must issue certificates of analysis, with supporting data required on those certificates.
Specific compounds required on a certificate: certificates must report whether the chemical profile conforms to labeled content for THC, THCA, CBD, CBDA, terpenes required by regulation, CBG, CBN, and any other compounds the department mandates.
ISO accreditation mandated: all laboratories performing compliance tests must obtain and maintain ISO/IEC 17025 accreditation as required by the department’s regulations.
Edible potency tolerances specified: edible products target 10 mg THC per serving with an initial allowable variance of ±12 percent and, after the bill’s referenced date, a tighter allowable deviation of ±10 percent; the department may set different variances for products under five milligrams total THC.
Performance and proficiency testing authorized but funded separately: the department may subject labs to blind proficiency or round‑robin performance testing to check consistency, but such programs are explicitly made subject to legislative appropriation.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Sampling scope and who may test
These subsections make clear that representative samples must be tested and that testing must be performed on the product’s final consumer form. They also restrict compliance testing to licensed testing laboratories and give the regulatory agency authority to develop criteria for which batches must be tested or retested. Practically, that means cultivators and manufacturers should expect batch holds pending sample collection and transfer to a third‑party lab, and labs must be prepared to perform testing only in permitted scopes of work.
Certificate of analysis content and contaminant standards
This paragraph specifies what certificates of analysis must cover: confirmation that labeled compound content matches the sample’s chemical profile and that contaminant levels are below department thresholds. It lists particular cannabinoids and terpenes for reporting and defines contaminants to include residual solvents, foreign materials, and microbiological impurities. The department is tasked with setting contaminant limits and directed to consult established references such as the American Herbal Pharmacopoeia and DPR guidance—meaning rulemaking will translate these references into enforceable thresholds.
Edible potency tolerances
The law sets a numeric framework for THC per serving in edibles: a 10 mg per serving target with an initial variance band and a later tighter tolerance, and it directs the department to make special variance adjustments for products with less than five milligrams total THC. That mechanism forces regulators to reconcile laboratory measurement uncertainty with consumer‑facing labeling and creates an explicit enforcement tolerance for potency tests.
Laboratory methods, accreditation, and proficiency testing
These clauses require the department to establish a standard cannabinoids test method (including SOPs) and authorize multiple methods or a reference laboratory. Laboratories must conduct testing consistent with competence standards and obtain and maintain ISO/IEC 17025 accreditation as the department’s regulations require. The department may also run performance testing programs—blind proficiency or round‑robin—to monitor inter‑laboratory consistency, although these programs depend on legislative funding. Together these provisions shift a great deal of technical standard‑setting to administrative rulemaking and to the labs’ operational capacity.
Out‑of‑spec protocols and sample disposition
When a test result falls outside authorized specifications, labs must follow SOPs to confirm or refute results and may only retest under limited circumstances (compromised test conditions or department authorization). After analysis, remaining sample portions must be destroyed according to department rules. These mechanics are important for dispute resolution, chain‑of‑custody integrity, and preventing reuse of retained sample material in ways that could compromise traceability.
Chain of custody and onsite testing exceptions
Presale inspections, testing transfers, and transportation must adhere to a specified chain of custody protocol, which will be crucial for linking test certificates to specific retail batches. The statute also allows licensees to perform onsite testing for internal quality control, including testing product from other licensees, but explicitly states that such onsite testing is not department‑certified and does not satisfy the compliance testing obligation—maintaining the primacy of third‑party certified lab results.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Consumers and patients: clearer reporting on compound profiles and contaminant limits improves product safety and reduces uncertainty about labeled potency and purity, making purchases more predictable.
- Retailers and brands focused on consistency: standardized methods and certificates of analysis make it easier to compare lots and to defend labeling claims across suppliers and stores.
- Regulators and public health agencies: specific statutory hooks (contaminant definitions, reference materials to consider, and authority for proficiency testing) provide firmer grounds for enforcement and public health investigations.
- Larger, accredited testing laboratories: labs that already hold or can obtain ISO/IEC 17025 accreditation and standardized methods gain competitive advantage from rules that raise entry barriers for lower‑capability providers.
Who Bears the Cost
- Small and medium cultivators and manufacturers: additional pre‑sale testing requirements, batch holds, and potential rejections increase per‑batch costs and inventory risk, disproportionately affecting operations with thin margins.
- Testing laboratories (particularly smaller labs): the ISO/IEC 17025 accreditation, standardized methods, and any performance testing impose upfront compliance costs, ongoing quality management expenses, and potential throughput bottlenecks.
- The Department (regulator): the statute delegates significant technical work—method development, setting contaminant levels, running proficiency programs—but provides no dedicated funding mechanism; the department will need resources to write, implement, and oversee complex rules.
- Retailers and patients in tight supply markets: tighter testing rules and lab capacity constraints could slow product release, causing temporary shortages or price pressure, especially where local supply chains are already strained.
Key Issues
The Core Tension
AB1027 pits two legitimate goals against one another: it seeks uniform, science‑based testing and stronger consumer protection through standardized methods, accreditation, and reporting, but doing so concentrates cost and complexity on small producers, testing labs, and the regulator—raising the question whether stricter technical standards will improve public safety or simply raise barriers to market participation unless accompanied by sufficient administrative capacity and transitional support.
The bill centralizes a lot of technical authority in administrative rulemaking. Many of the law’s operational effects depend on the department’s future choices—what compounds and terpenes to require, precise contaminant thresholds, the scope of acceptable test methods, and the frequency and design of performance testing.
That creates implementation risk: regulated parties must wait for detailed regulations to know exact compliance obligations, and those regulations will determine the real cost and feasibility of compliance.
Another practical tension is test precision versus enforceability. The statute attempts to address laboratory variability with standardized methods, accreditation, and performance testing, but it also imposes numeric tolerances (notably for edible THC per serving).
Laboratories and producers will need to reconcile analytical measurement uncertainty with strict labeling tolerances. The requirement that labs destroy leftover sample material helps traceability and biosecurity, but it reduces the availability of retained material for independent dispute resolution or confirmatory testing unless the regulations provide for exceptions.
Finally, several oversight measures—most importantly, proficiency and performance testing—are made subject to appropriation. That creates a gap between the statute’s quality‑assurance ambitions and the regulator’s funded capacity to execute them; without dedicated funding, intended improvements in inter‑lab consistency may be slow to materialize, leaving the marketplace with stricter rules but uneven enforcement.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.